Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX43 in Recurrent/Metastatic Esophageal Squamous Cell Carcinoma
NCT06769113Phase 2Recruiting
- Sponsor
- Henlius
- Start
- Jan 2025
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX43 in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Henlius. Started Jan 2025; status: recruiting.
02
Drugs
HLX43
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06769113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06769113.